Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

STOCKHOLM, Nov. 27, 2023 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that it has finalized the development of an updated formulation of fostrox,…